EOLS - Evolus, Inc.

Insider Sale by Moatazedi David (See Remarks)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

3 days ago, Moatazedi David, serving as See Remarks at Evolus, Inc. (EOLS), sold 13,669 shares at $4.75 per share, for a total transaction value of $64,929.00. Following this transaction, Moatazedi David now holds 604,700 shares of EOLS.

This sale represents a 2.00% decrease in Moatazedi David's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Friday, March 20, 2026 and publicly disclosed via SEC Form 4 filing on Friday, March 20, 2026, meaning the disclosure happened on the same day as the trade.

Evolus, Inc. operates in the HEALTHCARE sector, specifically within the DRUG MANUFACTURERS - SPECIALTY & GENERIC industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Moatazedi David

Moatazedi David

See Remarks

David Moatazedi is the President, Chief Executive Officer, and a Class III director of Evolus, Inc. (NASDAQ: EOLS), a life sciences company specializing in medical aesthetics, where he has served since May 2018.[[1]](https://www.tradingview.com/news/tradingview:5dfb77c02722a:0-evolus-director-david-moatazedi-sells-shares/)[[2]](https://fintool.com/app/research/companies/EOLS/people/david-moatazedi)[[6]](https://investors.evolus.com/governance/board-of-directors/default.aspx)[[7]](https://investors.evolus.com/governance/executive-management/default.aspx) Aged 47, he leads the company's operations from its headquarters in Orange County, California, and holds significant equity ownership of approximately 364,927 to 1,668,191 shares as of mid-2025, reflecting strong alignment with shareholders.[[1]](https://www.tradingview.com/news/tradingview:5dfb77c02722a:0-evolus-director-david-moatazedi-sells-shares/)[[2]](https://fintool.com/app/research/companies/EOLS/people/david-moatazedi)[[3]](https://www.gurufocus.com/insider/60985/david-moatazedi) Prior to Evolus, Moatazedi was Senior Vice President and Division Head of U.S. Medical Aesthetics at Allergan, Inc. from March 2016 to May 2018, overseeing facial aesthetics, plastic surgery, regenerative medicine, body contouring, and skin care, and held earlier commercial roles at Novartis Pharmaceuticals.[[2]](https://fintool.com/app/research/companies/EOLS/people/david-moatazedi) He also served as a director at Obalon Therapeutics Inc. (2019) and ReShape Lifesciences Inc. (2017).[[3]](https://www.gurufocus.com/insider/60985/david-moatazedi) Moatazedi earned an MBA from Pepperdine University and a BA from California State University, Long Beach.[[2]](https://fintool.com/app/research/companies/EOLS/people/david-moatazedi) As a corporate insider listed as 'See Remarks,' he has conducted multiple share sales, including 127,905 shares in June 2025 for $1,283,195 and others totaling net sales of over 816,555 shares in recent periods.[[1]](https://www.tradingview.com/news/tradingview:5dfb77c02722a:0-evolus-director-david-moatazedi-sells-shares/)[[3]](https://www.gurufocus.com/insider/60985/david-moatazedi)

View full insider profile →

Trade Price

$4.75

Quantity

13,669

Total Value

$64,929.00

Shares Owned

604,700

Trade Date

Friday, March 20, 2026

3 days ago

SEC Filing Date

Friday, March 20, 2026

HEALTHCAREDRUG MANUFACTURERS - SPECIALTY & GENERIC

About Evolus, Inc.

Company Overview

No company information available
View news mentioning EOLS

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/4951851

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime